(CARA) Cara Therapeutic - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US1407551092
CARA: Chronic Pain Relief, Pruritus Treatment, Dialysis Pain Management
Cara Therapeutics, Inc. (NASDAQ:CARA) is a biopharmaceutical company specializing in the development of innovative therapeutics for chronic pruritus, a condition characterized by severe itching that can significantly impact quality of life. The companys lead product, KORSUVA (difelikefalin) injection, is approved for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. This product addresses a significant unmet medical need, as pruritus in CKD patients is often resistant to conventional treatments.
In addition to KORSUVA, Cara Therapeutics is advancing Oral difelikefalin, which is currently in Phase II/III clinical trials for the treatment of chronic pruritus associated with notalgia paresthetica, a condition causing intense itching near the spine. The company has established strategic partnerships to expand its global reach, including agreements with Maruishi Pharmaceutical Co., Ltd. for the development of difelikefalin-based products in Japan, Vifor Fresenius Medical Care Renal Pharma Ltd. for the commercialization of KORSUVA in dialysis patients, and Chong Kun Dang Pharmaceutical Corporation for the development and commercialization of difelikefalin products in South Korea.
Cara Therapeutics, Inc. was founded in 2004 and is headquartered in Stamford, Connecticut. The company has established itself as a leader in the development of peripherally acting kappa opioid receptor agonists, a novel approach to treating pruritus without the central nervous system side effects associated with traditional opioid therapies.
Additional Sources for CARA Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
CARA Stock Overview
| Market Cap in USD | 22m |
| Sector | Healthcare |
| Industry | Biotechnology |
| GiC Sub-Industry | Pharmaceuticals |
| IPO / Inception | 2014-01-31 |
CARA Stock Ratings
| Growth 5y | -85.4% |
| Fundamental | -21.7% |
| Dividend | 0.0% |
| Rel. Strength Industry | -46.1 |
| Analysts | 3/5 |
| Fair Price Momentum | 2.90 USD |
| Fair Price DCF | - |
CARA Dividends
No Dividends PaidCARA Growth Ratios
| Growth Correlation 3m | 23.1% |
| Growth Correlation 12m | -37.4% |
| Growth Correlation 5y | -94% |
| CAGR 5y | -46.59% |
| CAGR/Max DD 5y | -0.47 |
| Sharpe Ratio 12m | -0.53 |
| Alpha | -50.79 |
| Beta | 0.15 |
| Volatility | 70.27% |
| Current Volume | 2.6k |
| Average Volume 20d | 12.3k |
As of March 15, 2025, the stock is trading at USD 5.13 with a total of 2,562 shares traded.
Over the past week, the price has changed by +4.27%, over one month by -1.35%, over three months by +65.70% and over the past year by -45.65%.
Neither. Based on ValueRay Fundamental Analyses, Cara Therapeutic is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -21.65 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of CARA as of March 2025 is 2.90. This means that CARA is currently overvalued and has a potential downside of -43.47%.
Cara Therapeutic has received a consensus analysts rating of 3.00. Therefor, it is recommend to hold CARA.
- Strong Buy: 0
- Buy: 0
- Hold: 2
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, CARA Cara Therapeutic will be worth about 3.1 in March 2026. The stock is currently trading at 5.13. This means that the stock has a potential downside of -38.79%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 12 | 133.9% |
| Analysts Target Price | 12.1 | 136.3% |
| ValueRay Target Price | 3.1 | -38.8% |